{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Hepatocellular+Carcinoma", "query": { "condition": "Stage III Hepatocellular Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+III+Hepatocellular+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T02:11:29.236Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03298451", "title": "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab (Regimen 1)", "type": "DRUG" }, { "name": "Tremelimumab (Regimen 2)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Durvalumab (Regimen 1)", "type": "DRUG" }, { "name": "Durvalumab (Regimen 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1324, "start_date": "2017-10-11", "completion_date": "2026-08-27", "has_results": true, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 20, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298451" }, { "nct_id": "NCT00901901", "title": "Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Erlotinib (Tarceva)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 732, "start_date": "2009-05-21", "completion_date": "2018-05-23", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 23, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Gainesville, Florida + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00901901" }, { "nct_id": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-Related Non-Hodgkin Lymphoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Hepatocellular Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Non-Hodgkin Lymphoma", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Malignant Neoplasm", "Refractory Classic Hodgkin Lymphoma", "Refractory Malignant Neoplasm", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Antiretroviral Therapy", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-04-04", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595866" }, { "nct_id": "NCT00617981", "title": "Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "ThermoDox", "type": "DRUG" }, { "name": "5% Dextrose Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2008-05", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 9, "location_summary": "Los Angeles, California • Jacksonville, Florida • Louisville, Kentucky + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617981" }, { "nct_id": "NCT03211416", "title": "Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Adult Hepatocellular Carcinoma", "Child-Pugh Class A", "Stage III Hepatocellular Carcinoma", "Stage IIIA Hepatocellular Carcinoma", "Stage IIIB Hepatocellular Carcinoma", "Stage IIIC Hepatocellular Carcinoma", "Stage IV Hepatocellular Carcinoma", "Stage IVA Hepatocellular Carcinoma", "Stage IVB Hepatocellular Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2017-12-07", "completion_date": "2025-08-15", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 2, "location_summary": "Chicago, Illinois • Buffalo, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03211416" }, { "nct_id": "NCT05199285", "title": "A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-19", "completion_date": "2025-09-04", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Miami, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199285" }, { "nct_id": "NCT04605731", "title": "Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-08-03", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04605731" }, { "nct_id": "NCT00253708", "title": "Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "massage therapy", "type": "PROCEDURE" }, { "name": "pain therapy", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 39, "start_date": "2004-12-01", "completion_date": "2013-01-01", "has_results": true, "last_update_posted_date": "2017-08-07", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253708" }, { "nct_id": "NCT00082823", "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 2, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082823" }, { "nct_id": "NCT06349642", "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Early Stage Triple-Negative Breast Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Skin Neoplasm", "Metastatic Malignant Solid Neoplasm", "Resectable Lung Non-Small Cell Carcinoma", "Early Stage Lung Non-Small Cell Carcinoma", "Resectable Malignant Solid Neoplasm", "Resectable Triple-Negative Breast Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Recurrent Cervical Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Tissue Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2024-04-24", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-05-22T02:11:29.236Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06349642" } ] }